Latest / Decera Clinical Education Oncology Podcast
Experiences With Oral SERDs for HR+/HER2- Metastatic Breast Cancer
In this episode, Manali Bhave, MD; Annalise Labatut, PharmD, BCOP; and nurse practitioner Jamie L. Carroll, CNP, APRN, MSN, begin by discussing the landmark EMERALD study that led to FDA approval of elacestrant, the first oral selective estrogen receptor degrader (SERD) for treatment of hormone receptor–positive/HER2-negative metastatic breast cancer. Dr. Bhave also briefly reviews ongoing clinical trials of other oral SERDs for estrogen receptor–positive/HER2-negative metastatic breast cancer.
Next, the panel discusses the possible adverse effects with elacestrant, potential drug–drug…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.